Jeff Bolle doesn’t want to know how much time he has left. In late 2022, he was diagnosed with stage 4 bile duct cancer, which has a low long-term survival rate. Still, doctors felt hopeful that Bolle, who was very healthy prior to diagnosis, would respond well to treatment, which included surgery and six rounds of chemotherapy. But when Bolle arrived at a chemotherapy session in May, he learned some worrisome news: The drug he receives, cisplatin, wasn’t available. This meant his chemotherapy had to end after four rounds. Cisplatin is one of several chemotherapy drugs doctors are struggling to...